Alkem Laboratories is under the spotlight following substantial block transactions worth approximately ₹930 crore, with 17.88 lakh shares traded at ₹5,200 each on the National Stock Exchange. Notable buyers included ICICI Prudential Mutual Fund, which acquired 9.04 lakh shares, and HDFC Mutual Fund, with 5.1 lakh shares. The selling entities included Jayanti Sinha and the Samprada & Nanhamati Singh Family Trust. Additionally, Alkem launched semaglutide pre-filled syringes in India for diabetes management, priced at ₹350, marking a significant addition to its product line. In its Q4FY26 results, Alkem reported a 40.7% year-on-year increase in pre-exceptional profit, reaching ₹557.8 crore, driven by strong growth in both domestic and international markets. Domestic sales rose by 8.8% to ₹2,324.5 crore, while international revenue increased by 25.4% to ₹1,222 crore. However, net profit after exceptional items fell by 22.7% to ₹236.5 crore due to one-time charges of around ₹135 crore.